Can‑Fite BioPharma Ltd. secured a Canadian patent allowance for its orally bioavailable A3 adenosine receptor agonist Namodenoson, covering its use as an anti‑obesity therapy. The allowance was granted on February 9 2026 and complements existing U.S. and Australian patents.
The allowance protects the anti‑obesity indication, a market projected to reach $60.5 billion by 2030. The decision expands the company’s intellectual‑property footprint in a high‑growth segment and positions it to pursue licensing or direct commercialization in Canada.
Pre‑clinical studies showed Namodenoson increased adiponectin levels and reduced body weight, while a Phase IIa MASH study reported a 2.3 % weight loss after three months of treatment. The Canadian patent reinforces the evidence base and supports the company’s broader A3AR platform strategy.
Can‑Fite’s CSO, Pnina Fishman, said the new patent “expands our intellectual property estate into metabolic indications such as fat loss, creating new development and partnering opportunities and reinforcing the long‑term value of our A3 adenosine receptor platform.” The company also secured a notice of allowance in Canada for a NASH indication in February 2024.
While the patent is a strategic milestone, Can‑Fite continues to face financial challenges, reporting ongoing losses, declining revenue, and negative free cash flow. The company recently completed a reverse stock split, and the new patent may help attract partners or investors to support future development.
The Canadian patent process requires the company to pay a final fee within four months to obtain full protection. Once granted, the patent will provide exclusive rights to the anti‑obesity indication in Canada, potentially opening a new revenue stream or licensing opportunity.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.